Breast cancer

This early-stage trial tests a new vaccine called ES2B-C001, with or without an immune booster (adjuvant), in 40 people with HER2-positive metastatic breast cancer who have already tried other treatments. The vaccine is designed to help the body's immune system recognize and atta…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while re…

This study tests a combination of two drugs—alpelisib (a targeted therapy) and fulvestrant (a hormone blocker)—in Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA mutation. The cancer must have worsened after prior…

This phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…

This study tests a combination of two experimental drugs (LEE011 and BYL719) plus a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the triple combination can better control the cancer. Participant…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This phase 3 study tests whether adding alpelisib (a targeted pill) to fulvestrant (a hormone-blocking shot) can slow cancer growth in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. Participants must have already tr…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

Researchers are testing whether adding pyrotinib, an oral drug that targets HER2-family proteins, to standard chemotherapy helps shrink HER2-low, hormone receptor-positive breast cancer before surgery. The trial enrolls about 48 women with early or locally advanced disease. Every…

This Phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug in 28-day cycle…

Researchers compare two schedules of partial breast irradiation after breast-conserving surgery in women with low-risk early breast cancer. One group receives radiation daily for one week, the other for three weeks. The trial measures breast appearance three years later and track…

Researchers are testing whether adding apatinib, a drug that blocks blood vessel growth, to a CDK4/6 inhibitor and hormone therapy helps control HR+/HER2- advanced breast cancer. The trial enrolls women aged 18 to 75 with confirmed HR-positive, HER2-negative invasive breast cance…

This trial tests whether women with advanced breast cancer (cN3) who had chemotherapy before surgery can safely skip an extra radiation dose to lymph nodes that no longer show signs of cancer. Half of the participants receive the standard extra radiation boost, while the other ha…

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

Researchers test whether giving mitomycin plus carboplatin before surgery helps people with BRCA1 or BRCA2 mutations and locally advanced triple-negative breast cancer. The trial compares this combination, followed by paclitaxel, against standard chemotherapy. About 30 adults wit…

This study compares two surgical approaches for breast cancer: one that removes extra tissue around the tumor (routine cavity shave margins) and one that uses a special device (Savi Scout®) to guide removal of only suspicious margins. About 204 women with early-stage breast cance…

This early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This study tests a shorter, more focused radiation treatment (hypofractionated partial breast irradiation) for women with early-stage breast cancer. The goal is to see if targeting only the tumor site can reduce side effects and improve cosmetic outcomes compared to standard whol…

Researchers are testing two experimental oral drugs, PF-07220060 and PF-07104091, combined with standard hormone therapy in people with advanced breast cancer and other solid tumors. The trial has two parts: one that finds the safest dose and another that tests the combination in…

This study tested whether a higher dose (500 mg) of the drug fulvestrant works better than the standard dose (250 mg) in postmenopausal women with a certain type of advanced breast cancer that had worsened after previous hormone therapy. The trial involved 736 participants and me…

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This early-stage trial tests a new approach for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. It combines a radioactive drug (lutetium NeoB) that targets cancer cells with a standard chemotherapy pill (capecitabi…

This study tests whether adding the experimental drug inavolisib to two standard treatments (palbociclib and fulvestrant) can slow cancer growth in people with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer. About 325 parti…

This early-phase trial is testing a new combination of drugs for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. The experimental treatment includes a radioactive drug (lutetium NeoB) that targets cancer cells, plu…

This phase 2 trial tests three drug combinations—fulvestrant alone, fulvestrant plus palbociclib, and fulvestrant plus palbociclib plus avelumab—in 220 people with ER+/HER2- metastatic breast cancer that has progressed after prior CDK inhibitor therapy. The goal is to see which c…

This phase 4 study is testing the safety of trastuzumab deruxtecan, a targeted antibody-drug combination, in 100 Indian adults with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Participants have already received at least one prior anti-HER…

This early-phase trial tests a combination of two drugs, cyclophosphamide and veliparib, in people with HER2-negative breast cancer that has spread or cannot be surgically removed. The main goal is to find the safest dose and check for side effects. Up to 35 participants will rec…

This phase 2 trial tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) against the standard combination of pembrolizumab plus chemotherapy. It includes 83 people with previously untreated, PD-L1-positive, advanced triple-negative breast c…

This phase 2 trial tests whether adding tucatinib to standard drugs trastuzumab and capecitabine can shrink tumors in people with advanced HER2+ breast cancer who have already tried several treatments. About 66 participants will receive the three-drug combination. The main goal i…

This early-phase trial tests a two-step treatment for advanced breast cancer that cannot be cured with surgery or radiation. First, patients receive a drug called talazoparib alone, then both talazoparib and avelumab together. The main goal is to check safety and side effects, wh…

Researchers are testing an experimental antibody-drug conjugate called TQB2102 in people with recurrent or metastatic breast cancer that has low levels of the HER2 protein. The trial enrolls about 542 adults who have not yet received chemotherapy for their advanced disease. Parti…

This study tests a drug called disitamab vedotin in 100 adults with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with HER2 protein and have had prior treatment. They receive the drug into a vein every two weeks. Researchers will check…

Researchers are reviewing medical records to see how well pyrotinib works and how safe it is in people with HER2-positive advanced breast cancer whose disease worsened after treatment with trastuzumab and pertuzumab. The study includes about 200 patients in China who received pyr…

This study provides continued access to the cancer drug palbociclib (IBRANCE) for up to 35 patients with breast or head and neck cancer who have already benefited from it in earlier Pfizer trials. Participants will keep taking their current treatment combination, which may includ…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study …

This large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This study tests a system called CONCURxP that uses a smart pill dispenser (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills as prescribed. About 410 patients will be split into two groups: one gets the full system…

This Phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (Kadcyla) can prevent breast cancer from returning in people with high-risk HER2-positive breast cancer. About 1,188 participants who still had cancer af…

This phase 3 trial tests whether adding the drug palbociclib to standard hormone therapy can help prevent breast cancer from coming back in people with a specific type of breast cancer (HR+/HER2-). About 405 participants who had surgery for a local or regional recurrence will rec…

This study tests whether precisely targeted radiation (SBRT) can treat a few growing cancer spots in patients with metastatic breast cancer, allowing them to stay on their current systemic therapy instead of switching to a new drug. Researchers will also look at whether circulati…

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…

This Phase 3 trial tests whether giving one type of chemotherapy before another, before surgery, changes the chances of staying cancer-free in people with locally advanced HER2-negative breast cancer. Participants receive either a taxane (docetaxel or paclitaxel) first, followed …

This study tests whether injecting a very dilute hydrogen peroxide solution directly into breast tumors can make standard radiotherapy more effective. Researchers are enrolling 184 adults with locally advanced or recurrent breast cancer. Participants will receive injections twice…

This study tests a new oral drug, vepdegestrant, combined with abemaciclib in people with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. About 37 adults will take both pills daily at home, with clinic visits every 4 weeks, to see if the comb…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This phase III trial tests whether a structured weight loss program can lower the risk of breast cancer recurrence in overweight or obese women who have been treated for early-stage breast cancer. Researchers will compare women who join the program with those who do not, tracking…

This trial studies women with breast cancer who need a mastectomy, radiation, and immediate breast reconstruction using their own abdominal tissue (DIEP flap). The goal is to compare giving radiation before surgery versus after surgery. Researchers will measure patient satisfacti…

This study looks at the long-term safety of a drug called TOL2506, which suppresses ovarian function, in people with hormone receptor-positive (HR+) breast cancer. It includes premenopausal women and men who already completed a previous study. Participants will take TOL2506 along…

This trial tests whether adding enzalutamide, a drug used for prostate cancer, to the standard hormone therapy fulvestrant helps women with a certain type of breast cancer. The study includes postmenopausal women with ER+/Her2- breast cancer who will receive the treatment for abo…

This trial tests whether radiation therapy alone can control breast cancer that has spread to nearby lymph nodes as well as surgery to remove those nodes. Women with stage II or III breast cancer who still have cancer in their sentinel lymph node after chemotherapy are randomly a…

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This study follows 400 women for 10 years to see how safe and effective Mentor MemoryGel Ultra High Profile breast implants are for breast reconstruction after mastectomy or for revision surgery. Researchers track problems like repeat surgeries, infection, and capsular contractur…

This study tests whether certain women with early-stage HER2-positive breast cancer can be treated with a targeted drug combination (PHESGO™) without chemotherapy. Researchers use specific markers to select patients whose tumors are highly dependent on the HER2 pathway. The goal …

This trial is testing a new material made from cow tissue, called AXM, to support breast implants during reconstruction surgery after breast cancer removal. The goal is to see if AXM works as well as or better than synthetic mesh, with fewer complications. Women with early-stage …

This study tests whether adding belzutifan to fulvestrant can slow or stop the growth of a certain type of advanced breast cancer (ER+/HER2-) that has worsened despite hormone therapy. About 120 adults with inoperable or metastatic disease will receive either the new combination …

This phase II trial tests whether adding an immunotherapy drug (atezolizumab) to a targeted therapy (olaparib) works better than olaparib alone for advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 patients with locally advanced or metastatic disease are…

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This trial tests two ways of giving chemotherapy after breast cancer surgery. One group gets the drugs doxorubicin and cyclophosphamide every two weeks, while the other gets them on a continuous schedule, and both groups then receive paclitaxel either every two weeks or weekly. T…

This early-stage trial tests an oral drug called RGT-419B in Chinese patients with advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative, as well as other advanced solid tumors. The main goal is to see if the drug is safe and tolerable, and to f…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This phase 1 trial tests whether a single, high-dose radiation treatment called stereotactic body partial breast irradiation (SB-PBI) can safely treat early-stage breast cancer after surgery. Researchers are enrolling about 30 adults with ductal carcinoma in situ or certain early…

This study looks at whether high-intensity interval training (HIIT) is better than moderate exercise for improving heart health in women who finished chemotherapy for breast cancer. About 158 participants will be assigned to either HIIT or moderate exercise to see which approach …

This study tests a program to help Black women with breast cancer stick to their prescribed treatments, like chemotherapy or hormone therapy. Researchers will compare the program to standard care in 250 women recently diagnosed with early-stage breast cancer. The goal is to see i…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-phase trial tested a drug called Z-endoxifen in 62 people with a type of breast cancer that has spread or come back. The goal was to find the safest dose and check for side effects. Z-endoxifen works by blocking estrogen, which some breast cancers need to grow.

This Phase 3 trial is testing an experimental drug called Dato-DXd against standard chemotherapy in 732 people with advanced HR-positive, HER2-negative breast cancer. Participants have already tried one or two prior chemotherapies. The study aims to see if Dato-DXd can slow cance…

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This trial is testing whether combining the targeted drug trastuzumab with either oral chemotherapy or hormone therapy can effectively treat stage I HER2-positive breast cancer. The study includes women aged 18-70 with small, lymph-node-negative tumors, divided into two groups ba…

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …

This phase III trial is testing whether the drug pyrotinib can further reduce the risk of breast cancer returning in women with HER2-positive early or locally advanced breast cancer who have already completed standard treatment with trastuzumab. Participants will be randomly assi…

This phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…

This study tests whether adding the experimental drug capivasertib to standard hormone therapy and CDK4/6 inhibitors can delay cancer growth in people with advanced HR+/HER2- breast cancer that cannot be removed by surgery or has spread. About 895 adults whose cancer has not resp…

This pilot trial is testing whether a lower-toxicity chemotherapy combination can be a feasible option for adults aged 70 and older with HER2-negative breast cancer. The study aims to see how well older patients tolerate the treatment and whether they can complete the planned cou…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This trial tests whether personalized nutrition counseling to increase fiber intake can help preserve the diversity of gut microbes in people undergoing treatment for early-stage triple-negative breast cancer. Participants are randomly assigned to receive either coaching from a r…

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This Phase 3 trial is testing a new daily pill called camizestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 5,500 people with ER+/HER2- early breast cancer who have a moderate-to-high risk of the cancer returning. Participants take the drug f…

This trial is testing whether an experimental drug called SHR-A1811 can slow the growth of HER2-low breast cancer that has returned or spread, compared to standard chemotherapy chosen by the doctor. The study enrolls about 551 adults whose tumors have low levels of HER2, a protei…

This study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …

This study tests whether adding vericiguat to standard heart failure care can improve heart function in people with breast cancer who developed heart problems after cancer treatment. Participants will be randomly assigned to receive either vericiguat plus usual care or usual care…

This study has two parts. First, it screens people with HR+ HER2-low metastatic breast cancer who are on standard CDK4/6 inhibitor therapy to find those with lingering tumor DNA in their blood—a sign of high relapse risk. Then, those high-risk patients receive the drug trastuzuma…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This phase III trial is testing whether adding the drug everolimus to standard hormone therapy can help prevent breast cancer from coming back in women with ER-positive, HER2-negative breast cancer who are at high risk of relapse. Participants have already completed at least one …

This trial is testing whether combining four drugs—anastrozole, palbociclib, trastuzumab, and pertuzumab—can safely and effectively treat HR-positive, HER2-positive metastatic breast cancer as a first-line therapy. The study involves people who have not received prior systemic tr…

This trial tests a new breast implant called REGENERA in women aged 40–70 who are having a lumpectomy for early-stage breast cancer. The implant is placed during the same surgery to fill the gap left by the removed tumor. The study aims to see if the implant is safe and whether s…

This study tests an experimental oral drug called PMD-026 in people with metastatic breast cancer that has spread and is no longer curable. The drug targets a protein called RSK2 found in some tumors. The trial will check safety and how well the drug works alone or with another h…

This study looks at whether a 16-20 week exercise and coaching program can reduce inflammation and protect blood vessel health in Black and White women undergoing chemotherapy for breast cancer. Researchers will measure fitness, blood vessel function, and quality of life. The goa…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…

This study is for people with a high-risk type of breast cancer (ER+/HER2-) who have finished initial treatment but still face a chance of the cancer coming back. Researchers will use a simple blood test to look for tiny bits of tumor DNA. If found, participants will be randomly …

This study tests whether giving olaparib (a PARP inhibitor) alone or combined with durvalumab (an immunotherapy) before surgery can eliminate or shrink tumors in people with BRCA-mutated, HER2-negative early breast cancer. Participants receive one of the two treatments for 4–6 mo…

This study tests a combination of two drugs, capivasertib and fulvestrant, in 101 people with a specific type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and a CDK4/6 inhibitor. The goal is to see how long it takes before the next cancer t…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…

This study is for women with a low-risk type of breast cancer that has spread to nearby lymph nodes or is T3N0. It compares standard care (which includes radiation to the lymph node area) against skipping that extra radiation. The goal is to see if avoiding regional radiation wor…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…

This study compares two modern, wire-free methods for locating non-palpable breast lesions before surgery: radioguided occult lesion localization (ROLL) using a radioactive tracer, and magnetic seed localization. The goal is to see which technique more reliably achieves clear sur…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study is testing whether women over 55 with a specific low-risk type of breast cancer (luminal A) can avoid radiation after lumpectomy. Instead, they take hormone-blocking pills for 5 years. Researchers are tracking 500 women for 10 years to see how many have the cancer come…

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer…

This early-stage trial is testing whether focused ultrasound (sound waves aimed at tumors) combined with a low dose of the chemotherapy drug gemcitabine can boost the immune system's ability to fight early breast cancer. About 32 participants will receive either ultrasound, low-d…

This study tested whether adding the drug palbociclib for two years to standard hormone therapy (taken for at least five years) helps prevent breast cancer from coming back in people with early-stage HR+/HER2- breast cancer. About 5,800 participants with stage II or III cancer to…

This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The mai…

This study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants wil…

This study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations can slow down cancer growth. About 435 adults with metastatic breast cancer wi…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this ag…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…

This study tests whether closely monitoring arm swelling after breast cancer surgery and treating it early with a compression sleeve can prevent long-term lymphedema. 250 women who had many lymph nodes removed will be randomly assigned to either the monitoring program or usual ca…

This study looks at whether adding surgery or radiation to a standard drug combination (palbociclib plus letrozole) can help people with newly diagnosed stage IV ER+/HER2- breast cancer live longer. About 200 women with cancer that has spread beyond the breast will receive the dr…

This study tests a new drug (PF-07220060) plus letrozole against standard treatments for people with HR-positive, HER2-negative advanced or metastatic breast cancer who haven't had prior therapy for advanced disease. About 1,035 adults will be randomly assigned to either the new …

This study tests whether a web application can help breast cancer patients take their hormone therapy as prescribed. About 438 patients starting hormone therapy will either use the app or receive standard care. The goal is to see if the app improves medication adherence and quali…

This phase 2 trial is testing whether a combination of ribociclib (Kisqali) and letrozole can safely replace chemotherapy for people with high-risk ER+/HER2- breast cancer. About 1100 participants will first receive the drug combo before surgery. If their tumor shows a low risk o…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This study looks at whether a targeted therapy called palbociclib, taken for 2 years alongside standard hormone therapy, can help prevent breast cancer from coming back in older patients with high-risk ER+/HER2- early breast cancer. The goal is to offer an effective alternative t…

This study tests whether extra care from a team of heart doctors, dietitians, exercise therapists, pharmacists, and physiotherapists can reduce side effects in breast cancer patients receiving chemotherapy. About 80 participants will be randomly assigned to either the team interv…

This study tests if a combination of ribociclib (a targeted pill) and hormone therapy works better than standard chemotherapy for women with a common type of early breast cancer (HR+/HER2-). About 1,684 women with intermediate-risk disease are taking part. The goal is to see whic…

This study looks at whether women with early breast cancer (tumors smaller than 5 cm) and no signs of cancer in the lymph nodes can safely avoid axillary surgery. About 800 women will be randomly assigned to either have a sentinel lymph node biopsy or no surgery at all. The goal …

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants receive the drug intravenously, and doctors monitor tumor response using brain…

This phase 3 trial compares a standard 3-week radiation course to an experimental 2-week course for women with early-stage breast cancer. About 400 participants who had lumpectomy will receive whole breast radiation plus an extra boost to the tumor site. The study checks if the s…

This Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…

This study tests a modified radiation schedule for women aged 50 and older with early-stage, low-risk breast cancer. Instead of the standard every-other-day treatment over 10 days, participants receive five daily radiation sessions with a slightly lower dose each day. The goal is…

This study tests whether a single, focused radiation treatment works as well as five treatments for people with low-risk stage 0 or I breast cancer after a lumpectomy. About 134 participants will be randomly assigned to receive either one or five doses of radiation to the tumor a…

This phase 3 trial compares giving hormone therapy (aromatase inhibitors) at the same time as chemotherapy versus after chemotherapy in 1000 postmenopausal women with early breast cancer. The goal is to see which timing better prevents the cancer from coming back over 15 years. P…

This early-stage trial tests two drugs, alpelisib and sacituzumab govitecan, together in people with advanced HER2-negative breast cancer that has spread or come back. The main goal is to find the safest dose and check for side effects. About 18 adults are taking part in this stu…

This study compares two approaches for women with early-stage invasive breast cancer undergoing breast-conserving surgery: no axillary surgery versus sentinel lymph node biopsy. The goal is to see if avoiding axillary surgery leads to the same cancer outcomes while reducing compl…

This phase III trial tests whether a less extensive lymph node surgery (tailored axillary surgery) followed by radiotherapy works as well as the standard full lymph node removal in women with breast cancer that has spread to the lymph nodes. The study involves 1,500 participants …

This phase 3 trial tests whether adding capivasertib to standard fulvestrant therapy can slow cancer growth in people with advanced HR+/HER2- breast cancer. About 818 participants whose cancer worsened after hormone therapy will receive either the combination or a placebo plus fu…

This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plu…

This study looks at a new material called SC Derm, used in breast reconstruction after mastectomy for breast cancer. It compares how well this material works and its safety against other similar products. About 120 women aged 20 to 69 who are having a mastectomy and immediate imp…

This phase 2 trial is testing whether a combination of targeted cancer drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer without traditional chemotherapy. About 393 patients will receive these drugs as a subcutaneous injection, wit…

This trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…

This phase 3 study tests whether adding the targeted drug abemaciclib to standard hormone therapy helps prevent breast cancer from returning in people with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to lymph nodes. Over 5,600 pa…

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to two standard targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in people with HER2-enriched breast cancer. The study involves 51 participants and measures how many have no or…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This study aimed to test the safety and effectiveness of combining the drug ribociclib with hormone therapy and radiation for women aged 70 and older with a certain type of breast cancer. The goal was to control the disease without surgery. However, the study was withdrawn before…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…

This phase 3 trial tests whether adding the experimental drug ipatasertib to standard hormone therapy (fulvestrant) can slow the growth of advanced ER-positive, HER2-negative breast cancer. The study enrolls 250 postmenopausal women whose cancer worsened after initial treatment w…

This small study is testing whether hyperbaric oxygen therapy (HBOT) can help control the growth of breast cancer that has spread to the lungs. Ten women with advanced breast cancer and lung metastases will receive standard cancer treatment plus HBOT sessions. The goal is to see …

This Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…

This study looks at a way to help women under 40 with breast cancer keep their ability to have children after chemotherapy. Before starting chemo, participants receive hormone injections and tamoxifen to stimulate their ovaries, then eggs or embryos are frozen. The goal is to see…

This study compares the brand-name drug Ibrance (palbociclib) with a local generic version in 100 Iraqi women with stage IV hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works just as well and is as safe as the brand. Patients take the …

This study compares an oral version of the chemotherapy drug paclitaxel (Liporaxel) with the standard IV version (Taxol) in 549 people with recurrent or metastatic HER2-negative breast cancer. The goal is to see if the pill works as well or better at controlling the disease and i…

This study looks at whether ovarian stimulation and egg or embryo freezing is safe and doable for young women (ages 18–38) with early breast cancer who are about to start chemotherapy. The goal is to help preserve their fertility. Researchers will track how many eggs are collecte…

This study tests whether a highly focused type of radiation called stereotactic body radiation therapy (SBRT) can delay cancer progression in women with metastatic breast cancer who are starting their first treatment. About 154 participants will receive either standard therapy al…

This phase 2 trial is testing whether adding the targeted drug dalpiciclib to standard hormone therapy (letrozole) before surgery can improve outcomes for women with HR+/HER2- early-stage breast cancer. The study enrolls 100 women aged 18-70 whose tumors have a high genetic risk …

This Phase 3 trial is testing an experimental oral drug called ARV-471 against a standard injectable drug, fulvestrant, in people with a common type of advanced breast cancer (ER+/HER2-). The study includes 624 participants whose cancer has worsened after prior hormone-based trea…

This study tests whether combining hormone therapy, a targeted drug (palbociclib), and an immunotherapy (avelumab) can shrink early-stage, hormone-positive breast tumors before surgery. About 33 women with stage II-III breast cancer will receive the treatment for about 4 months, …

This phase 2 trial tests whether adding ribociclib to letrozole before surgery helps more women with ER-positive, HER2-negative early breast cancer achieve a low-risk score (PEPI 0) compared to letrozole alone. About 121 postmenopausal women with stage II or III breast cancer wil…

This study tests whether a combination of two pills (letrozole and abemaciclib) works as well as standard chemotherapy before surgery in women with a common type of early breast cancer (HR-positive, HER2-negative) that is at high or intermediate risk of coming back. About 200 wom…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…

This phase 3 trial is testing whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy for people with a specific type of advanced breast cancer called HER2-low, hormone receptor positive. The study includes 866 participants whose cancer ha…

This study tests a new treatment for women with metastatic breast cancer that has spread. It combines specially trained immune cells (HER2 BATs) that attack cancer cells with a drug called pembrolizumab that helps the immune system work better. The goal is to find a safe dose and…

This phase II trial is testing a less intense chemotherapy regimen for people with early-stage HER2-positive breast cancer. The experimental treatment combines paclitaxel with two targeted drugs (trastuzumab and pertuzumab), skipping the harsher anthracycline drugs. Researchers w…

This study compares a robotic surgical system (da Vinci SP) to traditional open surgery for nipple-sparing mastectomy in women with early-stage breast cancer. The trial involves 204 participants and will measure safety, cancer recurrence, and patient satisfaction. The goal is to …

This trial is testing whether giving a small dose of targeted radiation to a part of the breast tumor before standard chemotherapy can help the immune system fight the cancer more effectively. The study includes 40 people with high-risk or locally advanced breast cancer. After ra…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …

This Phase 3 trial tests a new experimental drug, vepdegestrant, combined with palbociclib against the standard treatment (letrozole plus palbociclib) for people with advanced ER+/HER2- breast cancer that has not been treated before. The study aims to see if the new combination w…

This study looks at whether young women with early-stage, hormone-sensitive breast cancer can temporarily stop their hormone therapy to try to get pregnant without raising their risk of cancer coming back. It involves 518 women aged 18 to 42 who have already been on hormone thera…

This Phase 3 trial is testing a new drug called gedatolisib combined with fulvestrant, with or without palbociclib, in about 700 people with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The goal is to see if this combination can slow cancer growth bet…

This phase 3 trial tested whether adding the drug everolimus to standard hormone therapy helps prevent breast cancer from returning in nearly 2,000 patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. Participants received either hormone therapy plus e…

This study looks at women with a very early form of breast cancer called ductal carcinoma in situ (DCIS). After surgery to remove the cancer, all women get radiation to the whole breast. Half also get an extra, stronger dose of radiation right where the cancer was. The goal is to…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapies (anastrozole, letrozole, or fulvestrant) can help slow cancer growth in postmenopausal women with a common type of advanced breast cancer (HR+, HER2-). About 463 women participated, and the…

This phase 2 study tests the drug abemaciclib, either alone or with tamoxifen, in 234 women with a specific type of advanced breast cancer (HR+, HER2-). The goal is to see if these treatments can slow cancer growth in patients whose disease has progressed after prior therapies. P…

This study tests whether a supervised exercise program (a mix of high-intensity cycling and strength training) done three times a week during chemotherapy can help shrink breast tumors and improve how much chemo patients can tolerate. About 100 women with breast cancer will be ra…

This phase 3 trial tests whether adding abemaciclib to standard hormone therapy (anastrozole or letrozole) can slow cancer growth in postmenopausal women with HR+ HER2- breast cancer that has spread or returned. About 493 women participated, receiving either the drug combination …

This study tests a one-time radiation treatment for early-stage breast cancer. After a lumpectomy, tiny radioactive seeds are placed directly into the breast to kill any remaining cancer cells. The goal is to see if this method is safe, works well, and costs less than standard da…

This study looks at whether women aged 50 and older with a very low-risk type of early breast cancer (called DCIS) can avoid radiation therapy after having breast-conserving surgery. The goal is to see if the cancer stays away without radiation, reducing unnecessary treatment and…

This study compares two types of radiation therapy for women with early-stage breast cancer after lumpectomy. One group receives standard CT-guided radiation, while the other receives a newer MRI-guided approach. The goal is to see if MRI-guided radiation works just as well at pr…

This study tests a one-week radiation therapy for breast cancer patients who need treatment to the chest or breast and nearby lymph nodes. About 197 participants will receive this shorter radiation course and be followed for 5 years to check for side effects, cancer return, and q…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapy can lower the chance of breast cancer returning in postmenopausal women with a high-risk type. About 123 participants will receive either hormone therapy alone or with abemaciclib for up to 2…

This phase 3 study tests a 3-month injection (TOL2506) to temporarily stop ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The goal is to see if it works well with hormone therapy (tamoxifen or aromatase inhibitors) to control the cancer. About 250 …

This study follows 170 women with early-stage HER2+ breast cancer who are receiving the biosimilar drug Zedora after surgery. Researchers want to see how well it prevents the cancer from coming back and how safe it is in real-world settings, where patients may have other health i…

This study aimed to see if the drug capivasertib could clear cancer DNA from the blood of women with ER-positive breast cancer who had finished initial treatment. The goal was to prevent the cancer from coming back or spreading. However, the study was withdrawn before any partici…

This Phase 2 trial is testing whether adding the drug ribociclib (Kisqali) to standard hormone therapy can improve outcomes for people with early-stage ER-positive breast cancer. The study involves 120 participants and focuses on clearing cancer DNA from the blood. The goal is to…

This trial compares two surgical flap techniques—Grisotti flap and reverse mirror Grisotti flap—for women with early-stage breast cancer in the central part of the breast. The study includes 106 women aged 25-70 with tumors up to 5 cm near the nipple. The main goal is to see whic…

This study tests a high-dose, precise radiation therapy called SBRT for people with breast cancer who cannot undergo surgery. Fifteen participants will receive five radiation treatments and be followed for five years to check for side effects and tumor response. The goal is to se…

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 adults with triple-n…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This phase 3 trial compares two chemotherapy regimens for women with non-triple negative breast cancer after surgery. One group gets epirubicin plus cyclophosphamide followed by docetaxel (EC-T), the other gets paclitaxel plus carboplatin (PCb). The study includes 1560 participan…

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help the immune system better attack HER2-positive breast cancer before surgery. About 90 women with early-stage, operable breast cancer will ta…

This phase 2 trial tests whether a newer drug, margetuximab, combined with chemotherapy, works better than the standard trastuzumab combination for HER2-positive breast cancer before surgery. The study includes 174 people with stage II or III disease who have a specific genetic v…

This phase 3 trial studies whether adding the drug abemaciclib (Verzenios) to standard hormone therapy helps prevent breast cancer from coming back in 1,260 women with high-risk, HR+/HER2- early breast cancer. Participants have already completed initial treatments like surgery or…

This study tests whether applying radiofrequency ablation (a heat treatment) to the area where a breast tumor was removed can kill any leftover cancer cells and reduce the need for a second surgery. It involves 104 women aged 50 and older with early-stage breast cancer. The goal …

This study tests a technique called axillary reverse mapping during breast cancer surgery. Doctors inject a radioactive tracer and blue dye to map the arm's lymph drainage, hoping to avoid damaging those vessels and reduce the risk of lymphedema (arm swelling). The study involves…

This study was designed to test whether a biosimilar version of pertuzumab (EG1206A) works as well as the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either the biosimilar or the original dr…

This phase 3 study tests whether the drug sacituzumab govitecan (Trodelvy) can help people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer growing. About 654 participants will receive either the new drug or one of three standard chemother…

This study tests whether a polyester mesh coated with fluoropolymer can reduce complications after breast reconstruction in women with breast cancer. One hundred women will receive either standard reconstruction or reconstruction with the coated mesh. The main goal is to see if t…

This phase 2 trial is testing whether doctors can safely reduce the amount of chemotherapy given to people with HER2-positive breast cancer by using imaging scans to guide treatment. The study involves 462 participants with stage II or III disease who receive a combination of dru…

This study looks at whether women aged 50 and older with a specific low-risk type of early breast cancer (luminal A) can safely skip radiation therapy after surgery. About 1,167 participants are randomly assigned to receive either standard radiation plus hormone therapy or just h…

This phase 2 trial is testing a combination of three drugs—atezolizumab, trastuzumab, and vinorelbine—in people with HER2-positive advanced or metastatic breast cancer that has already been treated with trastuzumab and other anti-HER2 therapies. The study focuses on patients whos…

This Phase 3 trial tests whether a combination of targeted drugs (trastuzumab, alpelisib, and possibly fulvestrant) can work better than standard chemotherapy for people with a specific genetic mutation (PIK3CA) in HER2+ advanced breast cancer. The study enrolled 27 participants …

This phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This study tests whether artificial intelligence can accurately classify breast microcalcifications seen on mammograms as benign or malignant. Microcalcifications are common and often prompt a biopsy, but only a few turn out to be cancer. The researchers will also explore combini…

This early-stage trial is testing whether a new radioactive imaging agent, called [99mTc]Tc-DARPinEc1-G3C, can safely and effectively visualize breast cancer tumors using SPECT/CT imaging. The study involves about 10 people with primary triple-negative or luminal breast cancer. P…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This trial tests whether tomosynthesis (a 3D X-ray technique) combined with synthetic 2D images can reduce the number of advanced and interval breast cancers compared to standard digital mammography. Over 10,000 women scheduled for routine screening will be randomly assigned to o…

This study is testing whether a special MRI that does not require a contrast dye injection can accurately detect breast cancer or other breast diseases. Over 1,000 women at risk or with suspected breast issues will receive the new MRI alongside standard care. The goal is to see i…

This study tests a low-cost, portable ultrasound device (POCUS) combined with artificial intelligence to detect breast cancer in women with suspicious symptoms. The goal is to see if this approach works as well as standard imaging, especially in places where expensive equipment i…

This study tests whether contrast-enhanced mammography (CEM) finds breast cancer more accurately than standard mammography in women who have already had breast cancer. About 1,647 women ages 30-85 will get both types of mammograms to compare detection rates and false alarms. The …

This study is testing whether a simple blood test can help rule out breast cancer in women who had a suspicious mammogram. About 75% of women called back for extra testing turn out to be fine, but they still go through stressful and unnecessary procedures. The goal is to use bloo…

This pilot study tests a smart bra that measures skin temperature to find breast abnormalities, including cancer. About 70 women with or without breast cancer will wear the device to see how well it detects tumors. If it works, it could offer a simple, portable screening option.

This early-stage study tests a new radioactive tracer called [18F]ISO-1 in PET scans for people with breast cancer. The tracer targets sigma-2 receptors, which are linked to how fast cancer cells multiply. Researchers want to see if the scan can measure tumor growth rates and hel…

This study tests whether a fluorescent dye called indocyanine green (ICG) can replace the current radioactive tracer (technetium) for finding sentinel lymph nodes in breast cancer patients. About 493 women with early-stage breast cancer will take part. Surgeons will first use the…

This study tests advanced ultrasound signal processing to make breast images clearer. Researchers will compare new beamforming methods to standard ultrasound in 252 women with breast findings like cysts or microcalcifications. The goal is to better see important features and tell…

This study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…

This phase 3 trial is comparing two types of mammograms—standard 2D digital mammography and newer 3D tomosynthesis—to see which is better at finding advanced breast cancers early. Over 108,000 women are taking part, and researchers will track cancer diagnoses over 4.5 years. The …

This study tests whether different amounts of progressive aerobic exercise can reduce risk factors for breast cancer in women who are at high risk. Participants will follow an exercise program, and researchers will measure changes in exercise capacity, body composition, and gene …

This study tests whether a 6-month program combining Bollywood-style dance classes and a fitness tracker can increase physical activity and improve metabolic health in South Asian Indian immigrant women aged 40-65 who are not very active. The goal is to see if this culturally tai…

This study tests whether a mobile application can help breast cancer survivors prevent lymphedema, a common and often permanent swelling of the arm after surgery. Participants who had breast cancer surgery at least one month ago will be randomly assigned to use the app or receive…

This study tests a web-based nurse navigator program designed to encourage breast cancer screening (mammograms, breast self-exams, and clinical exams) in women at high risk for breast cancer. 104 women aged 30-70 who haven't had a mammogram in the last year are participating. The…

This study tests whether a special surgical technique called Axillary Reverse Mapping (ARM) can prevent lymphedema (arm swelling) in breast cancer patients who need lymph node removal. The ARM technique aims to preserve the arm's lymph drainage during surgery. 100 patients will b…

This phase 2 trial tests whether denosumab, a drug that blocks RANKL signaling, can reduce mammographic breast density in premenopausal women with dense breasts. Dense breasts are a known risk factor for breast cancer. The study involves 210 women who will receive either denosuma…

This study tests whether wearing two layers of surgical gloves during paclitaxel chemotherapy can prevent nerve damage in the hands. About 104 breast cancer patients will be randomly assigned to wear the gloves or not. Researchers will compare changes in nerve pain and function b…

This phase IIB trial tests whether a low dose of tamoxifen (a hormone-blocking drug) can reduce breast cancer risk in people who received chest radiation therapy before age 40. The study involves 84 survivors and measures changes in breast density as a risk indicator. If successf…

This study tests a skin gel called GR1014-CG to see if it can prevent or reduce skin irritation caused by radiation therapy after breast cancer surgery. About 273 women will apply the gel before each radiation session for five days. The goal is to find a safe way to protect the s…

This study looks at whether massage therapy can reduce nerve problems like pain, numbness, and tingling caused by chemotherapy in people with breast or digestive system cancers. About 90 participants will receive massage sessions to see if it improves symptoms and quality of life…

This study aims to develop and test a shortened version of Mindfulness-Based Cognitive Therapy (MBCT) to improve mood in older African American/Black women who have had breast cancer and now have mild to moderate depression. About 23 participants will attend group sessions and re…

This study tests whether adding a photo guide to standard counseling helps reduce anxiety and depression in women with early-stage breast cancer who are about to start radiation therapy. About 62 participants will either receive standard verbal counseling alone or with a pictoria…

This study tests whether an AI system that analyzes social media posts can improve quality of life for breast cancer patients. 440 women will either use the AI system plus usual care or just usual care for 6 months. The goal is to see if personalized emotional support reduces anx…

This study looks at whether hypnosis can help women with early-stage breast cancer relax during surgery, possibly reducing the need for general anesthesia. About 50 women will try hypnosedation, a technique that uses words and images to keep them calm and awake while numb. The go…

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study tests whether a remotely delivered program that combines mindfulness, physical activity tracking, and social support is acceptable and feasible for people with metastatic breast cancer. The program lasts 8-12 weeks and includes a wearable activity tracker and weekly ch…

Researchers are testing a three-part art therapy program for women aged 45 and younger who have had breast cancer surgery. The program combines body, voice, and mind exercises. The trial measures changes in insomnia severity and overall physical, mental, and social wellbeing. It …

This study tests whether a tailored physical activity program can help lymphoma and breast cancer patients preserve their exercise ability, heart function, memory, and quality of life while undergoing cancer treatment. About 110 adults aged 18-85 with Hodgkin or non-Hodgkin lymph…

This study tests a 5-week computer-based memory training program for breast cancer survivors who have memory and attention problems after chemotherapy. Sixty women will be randomly assigned to either the full working memory training or a less challenging version. The goal is to s…

This study tests whether an interactive 3D tool, used during a standard surgical consultation, helps women feel more satisfied with the information they receive about breast reconstruction options. Researchers will also check if the tool improves satisfaction with their breasts a…

This pilot study tests a decision aid designed to help women with early-stage breast cancer choose between lumpectomy and mastectomy. The tool uses quality-of-life data from past patients to help women weigh the risks and benefits based on their own values. Researchers will see i…

This study tests whether a 16-week high-intensity interval training (HIIT) program on a stationary bike can improve thinking, memory, and heart health in women undergoing chemotherapy for breast cancer. Thirty participants will be randomly assigned to either HIIT or a stretching …

This study tests a 3-month intermittent fasting weight loss program in 36 adults who have completed treatment for breast cancer and are overweight or obese. Participants follow a 4:3 fasting schedule (3 modified fast days per week) and aim for 150 minutes of physical activity wee…

This trial tests whether a 12-week supervised aerobic exercise program can improve physical function, quality of life, and cognitive function in women who have finished treatment for early-stage breast cancer and are in remission. Researchers will measure blood levels of three bi…

This study tests whether a personalized support program led by a nurse can help prevent memory and thinking problems that often occur after chemotherapy in women with non-metastatic breast cancer. Fifty women will receive regular face-to-face and telephone interviews over 9 month…

This study tests whether temporarily freezing the nerves that supply the breast can reduce pain and the need for opioid painkillers after mastectomy. About 216 women having breast removal will receive either the freezing treatment or a sham procedure. The goal is to see if a sing…

This trial tests whether cognitive behavioral therapy for insomnia (CBT-I) can reduce cancer-related fatigue in breast cancer patients who also have chronic insomnia. Participants receive different doses of CBT-I, which focuses on changing sleep habits and thoughts. The study aim…

This study tests whether a single oral dose of cannabidiol (CBD) can reduce the anxiety people with advanced breast cancer feel before undergoing CT or PET scans. Participants are randomly assigned to receive either CBD or a placebo, and their anxiety levels are measured before a…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tested a 24-week weight loss program delivered via video calls for 22 breast cancer survivors who were overweight or obese. The goal was to see if the program was practical and well-liked, and whether it improved quality of life, physical activity, and mood. Participan…

This trial asks whether starting sexual health support early and systematically helps women with localized breast cancer feel better about their sexual well-being compared to waiting until they ask for help. Women aged 18 and older who are beginning treatment with surgery will re…

This study looks at whether a mobile health program that combines physical activity tracking with mindfulness lessons can help breast cancer survivors become more active and feel better. About 304 women who finished cancer treatment within the past 5 years will take part in a 24-…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This trial tests whether acupuncture can prevent taxane-induced peripheral neuropathy (TIPN) — nerve damage causing pain and tingling in arms and legs — from worsening in breast cancer patients receiving weekly taxane chemotherapy. Participants with early-stage breast cancer who …

This trial tests whether adding bupivacaine, a numbing medicine, directly into the surgical wound after a mastectomy can improve pain control and reduce the need for opioid painkillers. Participants receive either bupivacaine or a placebo through a drain placed in the wound, alon…

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This trial tests whether a three-week physiotherapy program, starting one week after breast reduction surgery, can reduce pain, improve posture, and boost quality of life. Forty women aged 18 to 50 who have had their first breast reduction will be split into two groups: one recei…

This study looks at whether starting hormone therapy every other day for one month, then switching to daily, helps women with early breast cancer take their medication as prescribed. About 240 participants will be randomly assigned to either the standard daily dose or the gradual…

This study tests whether structured hypnotherapy sessions can improve quality of life for women with breast cancer undergoing chemotherapy. Participants in the intervention group receive 10 hypnotherapy sessions alongside standard care, while the control group receives standard c…

This study tests if whole-body cryotherapy (brief exposure to extreme cold) can reduce joint pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. About 70 women will be randomly assigned to either a real or placebo cryotherapy session. Researchers will…

This study tests two ways to cool the scalp during chemotherapy to prevent hair loss in women with localized breast cancer. One uses a standard cold cap with a compression bandage, the other a cooling mask. Researchers will compare how well each prevents hair loss, and also look …

This study tests whether a cream made with caffeine can help prevent skin hardening and other complications in breast cancer patients who need radiation after mastectomy with tissue expander reconstruction. About 60 participants will use either the caffeine cream or a placebo cre…

This study tests whether a 10-week video-based stress management program (VSMART) is practical and helpful for 25 breast cancer survivors in Alabama. Participants join group discussions from home. The goal is to see if the program improves wellbeing and to gather feedback from su…

This pilot study tests whether a home-based virtual program of cardio and yoga (IM@Home) can help breast cancer patients undergoing radiation feel less fatigued and more active. Forty participants will wear a FitBit and attend online classes. The goal is to see if the program is …

This study looks at whether writing about your thoughts and feelings about breast cancer can improve quality of life. About 272 people recently diagnosed with breast cancer will be asked to write for 20 minutes once a week for four weeks. They will fill out questionnaires to meas…

This study is testing whether a 9-month, individually tailored exercise program can reduce physical fatigue and improve quality of life in 357 people with stage IV breast cancer. Participants work with a trained instructor to follow a personalized exercise plan. The main goal is …

This study tests whether a 20-week program of exercise alone or exercise combined with cognitive training can improve thinking and memory in breast cancer survivors. 108 women who have finished primary treatment will be assigned to one of three groups: dual-task training, exercis…

This study tests whether a type of pain education that teaches the brain's role in pain, combined with motivational interviewing, can reduce chronic pain in breast cancer survivors. 156 women who have finished primary treatment and still have pain will be randomly assigned to thi…

This study compares a single dose of radiation given during breast cancer surgery (IORT) to standard whole breast radiation given over weeks. The goal is to see if IORT causes less fatigue in women with low-risk early breast cancer. About 100 women aged 50 and older with small, h…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This study explores whether music therapy can reduce anxiety, fatigue, and other symptoms in women with breast cancer who are receiving chemotherapy. Twenty-four participants will take part in weekly group music sessions and use personalized playlists at home, alternating periods…

This study looks at whether a shorter, more intense course of radiation (accelerated radiation therapy) is safe and tolerable for women with breast cancer who have already had chemotherapy and surgery. About 88 participants will receive the accelerated radiation to the breast and…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study tests whether combining pain neuroscience education (teaching patients about how pain works) with a gradual, timed increase in physical activity can reduce chronic pain in breast cancer survivors. About 122 survivors who have finished cancer treatment will be randomly …

This study tests a mixed reality system called VascuLens 2.0 that projects 3D images of a patient's blood vessels onto their body during DIEP flap breast reconstruction surgery. The goal is to help surgeons make more accurate incisions, potentially reducing surgery time and compl…

This study tests whether a 30-minute education session with a radiation therapist, before standard radiotherapy, can reduce anxiety and improve quality of life for breast cancer patients. About 109 participants will be randomly assigned to either the extra session or standard car…

This study tests whether talking to an exercise specialist over the phone can help breast and colorectal cancer survivors become more active. Many people become less active after cancer treatment, and this program aims to change that. The trial includes 120 participants who recen…

This study tests whether a special cooling mat can reduce hot flashes and night sweats in people taking hormone therapy for breast or prostate cancer. About 40 participants will use the mat for 8 weeks and track their symptoms. The goal is to see if this simple, non-drug approach…

This study tests an internet-based program called SHINE to help breast cancer survivors manage sexual concerns after treatment. About 340 women who finished primary cancer treatment at least 12 weeks ago will join. Participants get online education and tools, and the study checks…

This study tests a web-based portal called YES (Young, Empowered & Strong) designed to help adolescent and young adult breast cancer survivors monitor and manage their symptoms. Researchers will compare the quality of life of 400 women who use the portal to those receiving standa…

This study looks at two treatments for vaginal dryness in women with estrogen receptor-positive breast cancer who are taking aromatase inhibitors. One group uses a vaginal estrogen ring that releases a low dose of estrogen over 90 days, while the other uses a non-hormonal vaginal…

This study tests whether eating only within a 10-hour window each day can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty makes it harder to recover from stress and can lead to loss of independence. The trial will enroll 30 participa…

This study tests a mobile game called UMAY that helps breast cancer patients imagine their immune cells attacking cancer cells. 80 women with locally advanced breast cancer will play the game or a placebo game at home alongside their usual chemotherapy. Researchers will measure c…

This study tests a mobile cognitive-behavioral therapy program called MAAT to help breast cancer survivors who have memory and concentration problems after chemotherapy. About 220 survivors who finished chemo 1-5 years ago will either use MAAT or receive supportive therapy. The g…

This study aimed to compare two ways of numbing the chest after a mastectomy: a targeted nerve block versus direct injection into the surgical area. It was planned for adults aged 18-80 undergoing unilateral mastectomy. However, the trial was withdrawn before enrolling any partic…

This study tests a web-based portal (YES) for women aged 18–39 newly diagnosed with breast cancer. The portal helps track symptoms, offers self-management tips, and connects users with peers. Researchers want to see if it reduces issues like vaginal dryness and improves well-bein…

This study tests if the DigniCap scalp cooling system can prevent hair loss in Black women with early-stage breast cancer undergoing chemotherapy. About 30 participants will use the cooling cap during chemo sessions. The goal is to see if it helps keep hair, reducing the need for…

This study is testing whether a special compression bra, called Mobiderm Intimate, can safely reduce breast swelling (edema) that often happens after breast cancer surgery and radiation. Thirty women who had breast-conserving surgery will wear the bra day and night for three week…

This study tests a non-invasive brain stimulation technique called prolonged continuous theta burst stimulation (pcTBS) to relieve nerve pain caused by chemotherapy in breast cancer patients. Forty women will receive either pcTBS or standard repetitive transcranial magnetic stimu…

This study aimed to see if offering aesthetic care (like makeup and skincare) to women who had a mastectomy or lumpectomy for breast cancer could improve their body image and quality of life. It planned to compare women who received these sessions with those who did not. However,…

This study tests whether a 12-week online yoga program can reduce fatigue and inflammation in women who have had breast cancer surgery. 229 participants are randomly assigned to either the yoga group or standard care. The goal is to see if yoga helps with energy, stress, and dail…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study looks at whether a genetic test on tumor samples can predict how well HER2-negative breast cancer will respond to standard treatments like chemotherapy or hormone therapy. About 1,100 people with stage I-III breast cancer are taking part. The goal is to see if this tes…

This study tests whether a less invasive ultrasound-guided biopsy can accurately tell if breast cancer has been completely wiped out by chemotherapy, compared to the standard method of checking during surgery. About 43 women with aggressive breast cancer types (triple negative or…

This study follows 25 women with advanced breast cancer to understand why the drug palbociclib stops working over time. Researchers collect blood and tumor samples before and after the cancer progresses to look for genetic and chemical changes. The goal is not to treat the diseas…

This pilot study is testing whether wearable activity trackers, like fitness watches, can help monitor fatigue in people with pancreatic or breast cancer who are undergoing treatment. Researchers want to see if patients will use the device daily and find it easy to use. The study…

This study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…

This study looks at whether a special type of breast scan, called molecular breast imaging, can help doctors predict how well chemotherapy is working in women with invasive breast cancer. About 96 women will get the scan before, during, and after treatment. The goal is to see if …

This study looks at what breast cancer survivors and their family members know about chemicals in personal care products that might affect hormones. Researchers also want to see if there is a link between excess weight and these chemicals. About 30 people from the Acres Home comm…

This study asks breast cancer patients about their thoughts on screening for lymphedema, a common side effect where the arm becomes swollen and painful after treatment. Researchers use a device called a perometer to measure arm size before and after surgery. The goal is to see if…

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study looks at whether it is practical to give women recovering from breast-conserving surgery or mastectomy with reconstruction immediate feedback from their recovery surveys. The tool, called BREAST-Q REACT, shows scores on physical well-being and arm function and offers t…

Breast cancer patients often face uncertainty about how surgery or radiation will affect their appearance. This trial compares a standard approach, where doctors explain outcomes verbally, with a new cloud-based platform that uses artificial intelligence to show patients simulate…

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

Researchers at Lund University are studying whether psychological resilience, a person's ability to cope with stress, is linked to biological markers in breast cancer patients. They will measure resilience through questionnaires and analyze tumor and blood samples for molecular s…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This observational study looks at fertility decisions and outcomes in young women diagnosed with breast cancer in China. Researchers will follow women who had no children before their diagnosis to see if they later gave birth, and how often they used fertility preservation method…

This study looks at 100 women with stage II or III breast cancer to see if proton beam radiation causes less damage to the heart and lungs than standard X-ray radiation. Participants receive either type of radiation as part of a larger trial. Researchers will measure changes in h…

This study looks at how normal breast tissue appears on MRI and mammogram to see if it can help predict breast cancer risk. Researchers are comparing images and health information from over 2,000 women, including those with and without breast cancer. The goal is to better underst…

This study follows over 3,600 women who received MemoryShape or MemoryGel breast implants for augmentation or reconstruction. Researchers track complications like rupture, connective tissue disease, and cancer over 10 years. The goal is to gather real-world safety data, not to te…

This study looks at whether certain genetic variations can predict which women with early-stage breast cancer will stop taking anastrozole, a common hormone therapy, because of joint and muscle pain. Researchers will follow about 1,046 postmenopausal women who are prescribed anas…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study looks back at over 1,000 women who had breast-conserving surgery for non-palpable breast lesions. It compares four techniques used to locate these hidden lesions: wire-guided localization, radioguided occult lesion localization, magnetic seeds, and carbon dye. The goal…

This study looks at whether giving breast cancer patients a graph of their own survey results—called Patient Reported Outcome Measures—helps them engage more with their care. About 925 women with a new breast cancer diagnosis will be randomly assigned to either receive their surv…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This early-stage trial will test two different versions of the experimental drug HRS-6209 in 21 healthy Chinese adults. The goal is to see how the body absorbs the old and new capsule forms, and whether a high-fat meal affects absorption. No treatment benefit is expected for part…

This study investigates whether searching for breast cancer signs—masses and calcifications—together or separately affects detection accuracy. Using simulated mammograms, non-expert participants will perform different search tasks to measure response times and error rates. The go…

This study explores whether a special MRI scan can serve as a non-invasive biomarker to predict how early breast cancer responds to immunotherapy. Researchers will compare MRI features with tissue and blood samples from about 10 patients with hormone receptor-negative, HER2-negat…

This study follows women with early-stage breast cancer who are about to receive paclitaxel chemotherapy, a treatment that often causes nerve damage. Researchers will use smartwatches and a mobile app to track physical activity, sleep, and stress, alongside clinical exams and ski…

This study follows breast cancer patients who have had curative surgery and are receiving hypofractionated radiation therapy—shorter treatment courses lasting one to three weeks. Researchers will track changes in breast skin, fibrosis, cosmetic appearance, and patient-reported ou…

This study is investigating whether genetic changes in tumor tissue and blood can predict how well people with hormone receptor-positive metastatic breast cancer respond to a combination of endocrine therapy and palbociclib. Researchers will collect tumor samples and blood from p…

This study is looking at why some people develop persistent pain after breast cancer surgery while others do not. Researchers will follow 220 adults undergoing breast cancer surgery, using questionnaires and a pain sensitivity test to identify risk factors. The goal is to find re…

This study aims to create a large collection of blood and tissue samples from people with breast cancer, as well as those at high risk. The samples will be stored and used for future research to better understand, diagnose, and treat breast cancer. Participants will also be asked…

This study aims to learn more about how inherited gene mutations, particularly in the BRCA1 and BRCA2 genes, affect the risk of developing breast and ovarian cancer. Researchers will follow participants with a family history of these cancers, tracking their medical history and fa…

This study is for women with breast cancer who are receiving a treatment that greatly lowers estrogen levels. Researchers want to see if this treatment changes how the heart works. They will use heart scans to measure blood flow in 90 women over two years. The goal is to learn mo…

This study looks back at medical records of 150 women with breast cancer to compare two minimally invasive ways of checking whether cancer has spread to lymph nodes under the arm: robotic-assisted and endoscopic-assisted sentinel lymph node biopsy. The goal is to see which method…

This study uses a special PET scan to measure brain inflammation in women with stage II–III breast cancer before and after chemotherapy. The goal is to see whether higher levels of inflammation are linked to memory and thinking problems, often called 'chemo brain.' Twenty women w…

This registry follows 94 women aged 50 and older with early-stage, low-risk breast cancer who received a single dose of radiation directly to the tumor site during lumpectomy (IORT). The goal is to monitor cancer recurrence, side effects, and patient satisfaction over time. Becau…

This study looks at how the drug ribociclib is actually used in everyday medical practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will analyze medical records from thousands of patients to see who gets the drug, how long they take it, and wha…

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whethe…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study looks at how chronic noncommunicable diseases like inflammatory bowel disease and breast cancer impact a person's ability to work. Researchers will follow 200 working-age adults for 12 months, collecting data on health, work performance, and well-being. The goal is to …

This study looks back at medical records of 1,950 breast cancer patients to build a tool that predicts whether lymph nodes are cancer-free after chemotherapy. The goal is to identify patients who could safely have a less invasive sentinel node biopsy instead of full lymph node re…

This study looks back at 1,400 women who had breast-conserving surgery for non-palpable breast lesions. It compares two methods used to find the lesion during surgery: injecting a radioactive substance (ROLL) or placing a tiny magnetic seed. The goal is to see which technique lea…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study tests five different reminder strategies to encourage women in Singapore who are overdue for mammograms to get screened. About 12,750 women aged 50-69 who have not had a mammogram in over two years will receive reminders by mail, with some getting a pre-scheduled appoi…

This study looks at how to best collect information about social and behavioral needs (like housing, food, or transportation) from women newly diagnosed with breast cancer. Researchers will compare different screening tools and methods (like chatbots or phone calls) to see which …

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This study examines whether medications given during mastectomy to keep blood pressure stable might affect the risk of breast cancer coming back. Researchers will review the records of 250 patients who had mastectomy over five years. They will look at which drugs were used and tr…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This study involves 15 postmenopausal women with metastatic ER+ breast cancer. Researchers are testing a special PET scan that uses a radioactive tracer to see estrogen receptors on tumors. The goal is to find the best way to measure these receptors, which could help doctors know…

The FATLAS study is looking at how body fat (adiposity) influences breast cancer at both the whole-body and cellular levels. Researchers will enroll 150 breast cancer patients with different body types (lean, overweight, obese) and collect blood, tumor tissue, and body measuremen…

This study is for people with HER2-positive metastatic breast cancer who have had a lasting response (complete or partial remission for over 2 years) on anti-HER2 therapy. Researchers will use a personalized blood test called Signatera to look for tiny amounts of cancer DNA. The …

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study looks at 625 people in Russia with high-risk early-stage breast cancer that is HER2-negative. Researchers want to find out how many have BRCA1 or BRCA2 gene mutations and what treatments they receive in real-world practice. Participants provide blood and tumor samples …

This study looks at why women in the Hauts-de-France region of France may wait longer to start breast cancer treatment, even though they get cancer at similar rates as elsewhere. Researchers will track 500 women from their first symptom to their first treatment, breaking down del…

This study tests a new program to help breast cancer patients return to work after treatment. It includes 16 working-age women who have work difficulties. The program offers meetings and support from a team of specialists. The goal is to see if this approach is practical and help…

This study looks at whether a physical exercise program can prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. About 70 participants will be randomly assigned to exercise or usual care. Researchers will use heart scans and blood …

This study looks at whether artificial intelligence (AI) can help radiologists find breast cancer earlier when reading mammograms. Researchers will review past mammograms from 785 women, some with breast cancer and some without, to compare how well doctors detect cancer with and …

This study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…

This study tracks over 1,400 breast cancer and lymphoma patients to see how chemotherapy affects memory, attention, and thinking skills. Researchers test patients before, right after, and up to years after treatment. The goal is to learn who is most at risk for 'chemo brain' and …

This study examines how genetic variations (SNPs) in certain genes influence how well the drug raloxifene works and its side effects in 600 patients with lobular carcinoma in situ (LCIS), a high-risk breast condition. Participants take raloxifene daily, and researchers sequence t…

This observational study looks at how diet, activity, and lifestyle factors relate to muscle strength and heart health in 14 postmenopausal breast cancer patients who received anthracycline chemotherapy. Researchers will measure changes in heart function, muscle energy, and blood…

This study looks at whether using loco-regional anesthesia (numbing a specific area) during breast cancer surgery can help prevent chronic pain that often lasts months or years after the operation. About 30% of women experience this long-term pain. Researchers will follow 1,500 p…

This study involves 2,200 women aged 50–67 to see if personalized mammography screening, based on genetic and lifestyle risk factors, is safe and acceptable. Half the women receive standard biennial mammograms, while the other half get a risk assessment and a tailored screening s…

This study reviews medical records of 75 women who had a preventive nipple-sparing mastectomy (removing breast tissue while keeping the nipple). The goal is to see how often complications occur within 42 days after surgery. Researchers also check if the surgery successfully remov…

This study follows 132 young breast cancer patients who had chemotherapy, with or without a fertility preservation procedure (controlled ovarian hyperstimulation). Researchers track how many become pregnant and give birth over the long term. The goal is to understand how cancer t…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study tracks 65 people with metastatic breast cancer to see if a blood test that finds cancer cells (called circulating tumor cells) helps doctors choose the right treatment and check if it's working. Participants give blood samples and doctors answer surveys about how usefu…

This study watches how women with a certain type of advanced breast cancer are treated with the drug ribociclib in everyday medical practice in France. It does not give any new treatment but simply collects information on dosing, side effects, and how long the drug works. About 1…

This study follows women who are cancer-free three or more years after early breast cancer treatment. Researchers want to see if things like patient traits, cancer type, or treatment side effects affect long-term quality of life. Participants fill out short questionnaires about e…

This study tracks 20 women with breast cancer to see if radiotherapy causes muscle loss outside the treated area and how it relates to fatigue. Participants complete fatigue questionnaires and get CT scans at four time points: start, end, and 1 and 3 months after treatment. The g…

This study looks at whether adding a polygenic risk score (a blood test that estimates genetic risk) to standard risk tools helps high-risk women make decisions about breast cancer prevention. About 737 women aged 35-75 with elevated risk are involved. The goal is to see if the s…

This study looks back at 88 women who had two-stage breast reconstruction after mastectomy for breast cancer. It compares complication rates between nano- and microtextured tissue expanders and checks how prior radiotherapy affects outcomes. The goal is to find which expander typ…

This study tests a new PET/CT scan that uses a tracer called 18F-FluorThanatrace to measure PARP-1 activity in breast cancer tumors. About 50 adults with known or suspected breast cancer will get one or two scans. The goal is to see how well the scan detects cancer activity and c…

This study examines stored tumor tissue and blood samples from 22 women with early breast cancer to find genetic or chemical markers that might predict whether the cancer will spread to the brain. Researchers will compare women whose cancer did spread to the brain with those whos…

This study is collecting tumor and blood samples from 268 women with early breast cancer before they receive standard chemotherapy. Researchers want to see if certain immune-related factors in the tumor and circulating tumor DNA can predict whether the cancer will completely disa…

This study looks at fertility, pregnancy, and contraception in women diagnosed with breast cancer between ages 18 and 50. Researchers will collect data from 22,000 patients to understand how cancer treatments affect their ability to have children and the health of their newborns.…

This study tests whether giving breast cancer treatment based on each tumor's unique genetic makeup works better than standard therapy. About 200 people with large or aggressive breast tumors will receive a personalized drug plan before surgery. Researchers will track how well th…

This study follows over 1,300 women aged 40 or younger who were recently diagnosed with breast cancer. Researchers collect surveys, blood samples, and tumor tissue to learn about the disease, treatment side effects, and emotional challenges like fertility and menopause. The goal …

This study is testing a new tool called PORTENT that uses tumor samples and patient history to estimate the risk of breast cancer spreading (metastasis) in people with early-stage disease. Researchers will analyze tissue from 1000 patients and track their health for up to 10 year…

This study looks at how breast cancer itself may affect a woman's ability to have children later. Researchers are comparing egg quality and hormone responses in 100 women with breast cancer versus healthy egg donors. The goal is to understand why cancer can reduce the number and …

This study tests a program called the Sexual Health Empowerment (SHE) Project for women who are about to leave jail. The goal is to improve their understanding of cervical cancer, breast cancer, contraception, and sexually transmitted diseases. About 279 women will take part, and…

This study uses advanced brain scans to see how chemotherapy changes the brain in women aged 65 and older with early-stage breast cancer. Researchers will compare brain images and thinking tests taken before and after treatment. The goal is to better understand why some older pat…

This study collects tumor and blood samples from 241 women with HR+/HER2- advanced breast cancer before and after treatment with ribociclib (Kisqali) plus hormone therapy. Researchers will analyze DNA and RNA changes to find markers that predict who responds well and who develops…

This study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…

This study follows 220 women who had breast cancer surgery to understand why some develop persistent pain afterward. Researchers will track pain, mood, and daily function for 4 months to identify risk factors. The goal is to help doctors counsel patients and take steps to reduce …

This study follows 32 women who had breast reconstruction using a minimally invasive technique after mastectomy for breast cancer. Researchers measure shoulder muscle strength and function before surgery and at several points up to one year after. The goal is to see how well the …

This study collects information from about 866 women to better understand breast cancer that occurs during pregnancy, breastfeeding, or within a year after giving birth, as well as in women who become pregnant after breast cancer treatment. Researchers will track details like tum…

This study looks at two new models of follow-up care for people who have finished treatment for early-stage breast or colorectal cancer. The goal is to see if these models help survivors get the recommended cancer surveillance and preventive care. About 2450 adults from Kaiser Pe…

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This trial was designed to test whether adding aspirin to the immunotherapy drug avelumab could help the immune system fight triple-negative breast cancer. Participants would have received either avelumab alone or with aspirin for about 18 days, with biopsies and blood tests to m…

This study follows 500 breast cancer survivors (stage 0-IIIC) who were treated at City of Hope. Researchers will collect feedback and samples over time to understand long-term health, quality of life, and how the immune system responds to cancer. The goal is to improve follow-up …

This study looks at whether simple blood tests can tell if a woman's metastatic breast cancer is stable, so she can skip some routine scans. About 97 women with ER-positive/HER2-negative cancer will give blood samples at each scan visit. The goal is to create a smart algorithm th…

This study looks at whether a genetic test (BRCA1-like) can help doctors choose the best first chemotherapy for people with advanced triple-negative breast cancer. About 304 participants will receive either carboplatin-cyclophosphamide or paclitaxel, with or without the immunothe…

This study looks at women with newly diagnosed breast cancer who take part in exercise or mind-body programs for 3-6 weeks before their surgery. Researchers want to see if these programs help reduce stress, anxiety, and improve mood and quality of life. They also check for change…

This study tests whether community education and support can increase the number of women in Kenya who get screened for breast and cervical cancer. Researchers will enroll 5,400 women aged 30-55 and track how many complete recommended screenings and follow-up care. The goal is to…

This study follows 73 young women with breast cancer to see if certain genes make them more likely to lose fertility after chemotherapy. Researchers measure ovarian reserve (egg supply) before and up to 5 years after treatment. The goal is to better predict who might face fertili…

This study follows 200 women with breast cancer who are receiving doxorubicin and/or trastuzumab. Researchers want to learn how these drugs affect the heart over time and how factors like race, income, and access to healthcare play a role. Participants will have heart ultrasounds…

This study looks at how chemotherapy for breast cancer affects the heart, exercise ability, and fatigue. Researchers will compare breast cancer patients to people without cancer using heart MRIs and walking tests. The goal is to better understand and predict heart-related side ef…

The IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…

This study planned to test whether MRI-guided focused ultrasound could destroy breast tumors before mastectomy. The procedure was to be done under local anesthesia and sedation. However, the trial was withdrawn before enrolling any participants, so no results are available.

This study looks at how aerobic exercise changes the gut microbiome in breast cancer survivors and whether those changes relate to less fatigue. About 126 women who have finished primary treatment will take part. Researchers will measure gut bacteria from stool samples and track …

This study looks at whether high-intensity interval training (HIIT) can improve how breast cancer patients respond to chemotherapy before surgery. Fifty-five patients will either follow a personalized HIIT program or maintain their usual activity level. Researchers will analyze t…

This study aimed to understand why some women develop chronic pain after breast cancer surgery. Researchers planned to track psychological and social factors in women undergoing mastectomy or lumpectomy. However, the study was withdrawn before it started, so no results are availa…